Barclays kept its Buy rating and raised its Intuitive Surgical price target from $485 to $500 per share. This is a modest positive signal, but the story gives no new company results.
The change supports a more positive view of Intuitive Surgical, but it is one analyst's judgment. The story gives no new sales, profit, or procedure figures to show that the business itself changed.
Follow Intuitive Surgical (ISRG) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ISRG